MorphoSys AG is poised to increase investment in its late-stage pipeline in order to strengthen its position in the treatment of haematological cancers. The Germany-based company has one product on the global market, Monjuvi (tafasitamab) for diffuse large B cell lymphoma (DLBCL). It aims to have two commercial products by 2025. In addition, Phase 3 data for two partnered products – one in Alzheimer’s disease and the second for rheumatoid arthritis – are expected to be reported by the end of the year.
